Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02467452|
Recruitment Status : Completed
First Posted : June 10, 2015
Last Update Posted : October 29, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Chronic Obstructive Pulmonary Disease||Drug: BDP/FF/GB Drug: FlF/VI + Tiotropium||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1479 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multinational, Multicentre, Randomised, Open-Label, Active-Controlled, 26-Week, 2-Arm, Parallel Group Study to Evaluate the Non-Inferiority of Fixed Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) Administered Via Pressurized Metered-dose Inhaler (pMDI) Versus Fixed Combination Of Fluticasone Furoate Plus Vilanterol Administered Via Dry Powder Inhaler (DPI) (Relvar®) Plus Tiotropium Bromide (Spiriva®) for the Treatment of Patients With Chronic Obstructive Pulmonary Disease|
|Study Start Date :||May 2015|
|Actual Primary Completion Date :||January 2017|
|Actual Study Completion Date :||January 2017|
Drug: BDP/FF/GB Other name: CHF 5993 pMDI 100/6/12 mcg
Active Comparator: FlF/VI + Tiotropium
FlF/VI + Tiotropium Other name: Relvar DPI 100/25 mcg + Spiriva 18 mcg capsule
Drug: FlF/VI + Tiotropium
- Change from baseline in the Saint George's Respiratory Questionnaire (SGRQ) total score at Week 26. [ Time Frame: 26 weeks ]the primary efficacy variable is the numeric value of the change
- SGRQ response (change from baseline in total score ≤ -4) at Week 26. [ Time Frame: 26 weeks ]the secondary efficacy variable is derived as a categorisation of this value
- rced expiratory volume at one second (FEV1) response (change from baseline in pre-dose morning FEV1 ≥ 100 ml) at Week 26. [ Time Frame: 26 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||40 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Male and female adults aged ≥ 40 years with written informed consent obtained prior to any study-related procedure.
- Patients with a diagnosis of COPD at least 12 months before the screening visit (according to GOLD document updated 2014).
- Current smokers or ex-smokers who quit smoking at least 6 months prior to screening visit, with a smoking history of at least 10 pack years [pack-years = (number of cigarettes per day x number of years)/20].
- A post-bronchodilator FEV1 < 50% of the predicted normal value and a post-bronchodilator forced expiratory volume at one second (FEV1)/forced vital capacity (FVC) < 0.7 at least 10-15 min after 4 puffs (4 x 100 μg) of salbutamol pMDI. If this criterion is not met at screening, the test can be repeated once before randomisation.
A documented history of at least one exacerbation in the 12 months preceding the screening visit.
COPD exacerbation will be defined according to the following:
"A sustained worsening of the patient's condition (dyspnoea, cough and/or sputum production/purulence), from the stable state and beyond normal day-to-day variations, that is acute in onset and necessitates a change in regular medication in a patient with underlying COPD that includes prescriptions of systemic corticosteroids and/or antibiotics or need for hospitalization". Also documented visits to an emergency department due to COPD exacerbation are considered acceptable to fulfil this criterion.
Patients under double therapy for at least 2 months prior to screening visit with either:
- inhaled corticosteroids/long-acting β2-agonist combination (fixed or free), without regular use of short-acting muscarinic antagonist (regular use means 2 puffs 4 times per day at least) or
- inhaled corticosteroids/long-acting muscarinic antagonist free combination, without regular use of short-acting β2-agonist (regular use means 2 puffs 4 times per day at least) or
- Inhaled long-acting β2-agonist and inhaled long-acting muscarinic antagonist or
- Patients under monotherapy with long-acting muscarinic antagonist for at least 2 months prior to screening.
- Symptomatic patients at screening with a CAT score ≥10.
- A cooperative attitude and ability to use correctly the inhalers.
- A cooperative attitude and ability to use correctly the daily electronic Diary (eDiary).
- Pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential) UNLESS are willing to use one or more methods of contraception as defined in the protocol
- Patients with a current clinical diagnosis of asthma with a physician-judged need for inhaled or oral corticosteroid therapy
Patients requiring use of the following medications:
- A course of systemic steroids longer than 3 days for COPD exacerbation in the 4 weeks prior to screening
- A course of antibiotics for COPD exacerbation longer than 7 days in the 4 weeks prior to screening
- phosphodiesterase-4 (PDE4) inhibitors in the 4 weeks prior to screening
- Use of antibiotics for a lower respiratory tract infection (e.g pneumonia) in the 4 weeks prior to screening
- COPD exacerbation requiring prescriptions of systemic corticosteroids and/or antibiotics or hospitalization during the run-in period
- Patients treated with non-cardio selective β-blockers in the month preceding the screening visit or during the run-in period. Those patients may enter the study after non-selective β-blockers withdrawal and/or cardio selective β-blockers intake for at least 10 days before randomization
- Patients treated with long-acting antihistamines unless taken at stable regimen at least 2 months prior to screening and to be maintained constant during the study, or if taken as o re nata (PRN).
- Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia.
- Known respiratory disorders other than COPD which may impact the efficacy of the study drug according the investigator's judgment
- Patients who have clinically significant cardiovascular condition
Patients with atrial fibrillation (AF):
- Paroxysmal Atrial Fibrillation
- Persistent: AF episode either lasts longer than 7 days or requires termination by cardioversion, either with drugs or by direct current cardioversion (DCC) within 6 months from screening
- Long standing Persistent as defined by continuous atrial fibrillation diagnosed for less than 6 months with or without a rhythm control strategy
- Permanent: for at least 6 months with a resting ventricular rate ≥ 100/min controlled with a rate control strategy (i.e., selective β-blocker, calcium channel blocker, pacemaker placement, digoxin or ablation therapy)
- An abnormal and clinically significant 12-lead ECG which may impact the safety of the patient according to investigator's judgement Patients whose electrocardiogram (ECG12 lead) shows QT Interval Corrected by the Fridericia Correction Formula (QTcF) >450 ms for males or QTcF >470 ms for females at screening visit are not eligible (not applicable for patient with pacemaker)
- Medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that in the opinion of the investigator would prevent use of anticholinergic agents
- History of hypersensitivity to anticholinergics, β2-agonist, corticosteroids or any of the excipients contained in any of the formulations used in the trial which may raise contra-indications or impact the efficacy of the study drug according to the investigator's judgement
- Clinically significant laboratory abnormalities indicating a significant or unstable concomitant disease which may impact the efficacy or the safety of the study drug according to investigator's judgement
- Patients with hypokalaemia (serum potassium levels <3.5 milliequivalent per liter (mEq/L) (or 3.5 mmol/L)) or uncontrolled hyperkalaemia according to investigator's judgment
- Unstable concurrent disease: e.g. uncontrolled hyperthyroidism, uncontrolled diabetes mellitus or other endocrine disease; significant hepatic impairment; significant renal impairment; uncontrolled gastrointestinal disease (e.g. active peptic ulcer); uncontrolled neurological disease; uncontrolled haematological disease; uncontrolled autoimmune disorders, or other which may impact the efficacy or the safety of the study drug according to investigator's judgment.
- Patients with any history of malignancy likely to result in significant disability or likely to require significant medical or surgical intervention within the next six months (after V1) or with malignancy for which they are currently undergoing radiation therapy or chemotherapy
- History of alcohol abuse and/or substance/drug abuse within 12 months prior to screening visit
- Participation in another clinical trial where investigation drug was received less than 8 weeks prior to screening visit
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02467452
|Godollo, Hungary, 2100|
|Responsible Party:||Chiesi Farmaceutici S.p.A.|
|Other Study ID Numbers:||
2014-001487-35 ( EudraCT Number )
|First Posted:||June 10, 2015 Key Record Dates|
|Last Update Posted:||October 29, 2021|
|Last Verified:||October 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared Patient-level Data is anonymized to protect personally identifiable information.
Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.
|Access Criteria:||Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.|
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Peripheral Nervous System Agents
Physiological Effects of Drugs
Respiratory System Agents
Molecular Mechanisms of Pharmacological Action